Abstract: Certain triple nucleoside/tide reverse transcriptase inhibitor (NRTI) regimens containing tenofovir (TDF) have been associated with rapid early treatment failure. The mechanism is unknown, but may be at the level of drug transport. We measured the lipophilicity of the drugs [ 3 H]-lamivudine (3TC), -didanosine (ddI), -TDF and -ABC.
Introduction
Tenofovir disoproxil fumarate (TDF) is a potent nucleotide reverse transcriptase inhibitor (NtRTI) widely used in combination antiretroviral therapy. However, several studies have reported excessive and rapid early treatment failure in triple nucleoside reverse transcriptase inhibitor (NRTI) regimens containing TDF, lamivudine (3TC), didanosine (ddI), abacavir (ABC), (3TC+ddI or ABC+3TC) [1, 2] or in non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens with TDF+ddI as backbone in patients with high baseline viraemia [3] [4] [5] .
Phenotypic susceptibility to the drug combinations is reduced with the development of the K65R mutation in HIV-1 reverse transcriptase. Although the K65R mutation is rarely selected as compared with the thymidine analogue mutations associated with stavudine and zidovudine, the use of TDF+ABC, TDF+ddI and ABC+d4T in combination with 3TC or emtricitabine [6] is to be avoided due to the high levels of treatment failures.
Although the explanation for these high failure rates is unclear, overlapping resistance profiles, variable drug permeation into target cells, esterase cleavage of TDF, drug-drug and drug-food interactions at the level of influx/efflux transports may contribute to the acquisition of resistance. NRTIs and NtRTIs are prodrugs requiring intracellular phosphorylation to their active metabolites. Consequently, cellular entry of the drugs is important for successful inhibition of viral replication. Intracellular accumulation of a drug is dependent on several factors, including lipophilicity, ion trapping, protein binding, and drug transporters. Generally, the transport of most nucleoside analogues is mediated by one or more of the following nucleoside transporter systems: concentrative nucleoside transporters, (Na + -dependent), equilibrative nucleoside transporters (Na + -independent) and H + /peptide transporters [7] . Nevertheless, P-glycoprotein (P-gp), multi-drug resistance proteins (MRPs), breast cancer resistance protein (BCRP) and influx transporters such as human organic cation and anion transporters (hOCTs/hOATs) may mediate the transport of nucleoside and nucleotide analogues. There is some evidence that some NRTI/NtRTIs are substrates of P-gp, BCRP and MRPs [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , but there is no evidence that the efflux of ddI and TDF are BCRP-mediated. In other studies, the activities of P-gp and MRP were inhibited by ABC, 3TC and TDF [20] [21] [22] . However, evidence suggests that ddI does not inhibit P-gp activity and that 3TC is also not a substrate of P-gp [23] . There is evidence for the involvement of hOATs and hOCTs in the intracellular accumulation of some NRTI/NtRTIs [14, [24] [25] [26] . However, while TDF, ddI and 3TC are devoid of any BCRP inhibitory effect, ABC inhibits BCRP [21] .
We postulate that suboptimal concentrations as a consequence of drug-drug interactions at the level of transport may favour the emergence of drug resistant viruses. Here, the effects of the drug lipophilicity and drug transporter expression on the transport and cell-associated concentrations of [ 3 H]-3TC, -ddI, -TDF and -ABC were evaluated in primary human cells (which express transporters [27, 28] ) in the absence or presence of unlabelled interacting NRTI/NtRTI (singly or in combination).
Materials and Methods

Reagents
Blood buffy coats were purchased from the North West and North Wales Regional Blood Services (Liverpool, UK 
Octanol-saline partition coefficient
Since the cellular association of a drug within target cells is a composite of the physicochemical properties of the drug (passive diffusion, ion trapping), and active influx/efflux, we measured the lipophilicity of each drug ( [24] to establish the contribution of lipophilicity to drug uptake. Briefly, an equal volume of octanol and phosphate buffered saline (PBS) were presaturated by vigorously vortexing them for 5 min. The suspension was allowed to settle for 10 min before the upper saturated octanol layer was carefully removed and stored in a separate tube. Then of PBS. Then 540 µL aliquots of each compound were added to an equal volume of presaturated octanol and vortexed for 5 min. The samples were centrifuged (1000 g for 5 min). The concentrations of radiolabelled drug in a volume of the octanol (upper layer) and in a similar volume of saline (lower layer) were measured using scintillation counting. The octanol-saline partition coefficient was determined as a ratio of radiolabelled drug in the octanol phase to radiolabelled drug concentration in the saline phase.
Isolation of Peripheral Blood mononuclear cells (PBMCs)
11 PBMC samples were isolated from blood buffy coats using Lymphoprep (Alexis-sheild, Oslo, Norway), following the manufacturer's instructions. An aliquot of the PBMC samples were cryopreserved in fetal calf serum containing 10% dimethyl sulphoxide for batch analysis of membrane proteins by flow cytometry.
Drug-drug interaction studies of [ 3 H]-ABC, -3TC, -ddI and -TDF and effects of the unlabelled drugs
A series of preliminary transport experiments were performed to look at the concentration-ranging (0-100 µM) effects of the unlabelled drugs on cell-associated concentrations of the labelled drugs in T-lymphoblastoid cell lines (CEM(parental), CEM VBL (P-gp-overexpressing) and CEM E1000 (MRP1-overexpressing) and the monocytic cell line U937. The CEM and its variant cells have been also shown to express hOATs [28] .
We also used 50 µM dipyridamole, 100 µM of deoxycytidine (dC), deoxyinosine (dI) and deoxyguanosine (dG) as positive controls to inhibit the transport of the drugs. The concentrations used of these inhibitors were based on previous observations [27, 29, 30] . The isolated PBMCs (5  10 6 cells)
were incubated with 1 µM of [ 3 H]-3TC, -ddI, -TDF or -ABC in RPMI 1640 medium containing 10%
fetal calf serum at 4 °C or 37C, for 30-45 min in the absence or presence of fixed concentrations (50 µM) of the interacting unlabelled drugs (3TC, ddI, TDF, and ABC). In a limited number of PBMC samples, we investigated the effects of two drug combinations on the uptake of labelled compounds as described above. The incubations were terminated by centrifugation (15,000 g, 1 min at 0 °C). A-100 µL aliquot of the supernatant was counted for radioactivity and the cell pellets were washed three times in ice-cold phosphate buffered saline followed by rapid centrifugation before the pellets were solubilised in 100 µL of distilled water as described previously [31] and counted for radioactivity. Data were expressed as cellular association ratio (CAR), this being the ratio of the amount of radiolabelled drugs associated with the cell pellets to the amount in a similar volume of supernatant after incubation; cell volume of each PBMC being 0.4 pL [32] . In a separate experiment, cells were incubated with the tritiated compounds ([ 3 H]-3TC, -ddI and -TDF) in the absence or presence of 50 µM ABC as described. The assay was terminated by rapid centrifugation in a chilled microcentrifuge and the cell pellets were washed three times in ice-cold PBS as described, followed by three times of rapid freezing in liquid nitrogen and thawing at room temperature. The suspension was layered on top of 1 mL of ice-cold 42% percoll solution containing 0.25 M sucrose, 1.5 mM magnesium chloride, pH 7.1, and centrifuged (12,000 g, 30 min at 4 °C). After centrifugation, the radioactivity in the clear supernatant (assumed as intracellular drug) and in the pellet/debris, harvested from the bottom of the gradient (assumed as membrane-bound drug) were determined by scintillation counting.
Flow cytometric analysis of membrane proteins for P-gp, MRP1 and BCRP
PBMC expression of P-gp, MRP1 and BCRP were performed on the frozen samples as previously described [33, 34] .
Ethics: No ethical approval was required in the collection and use of the blood products from the blood transfusion services.
Statistical analysis
Data were expressed as mean ± S.D. Shapiro-Wilk test was used to assess the distribution of the data, followed by Kruskal-Wallis test to allow multiple comparisons of drug-treated samples to respective controls. In each case, significance between control and drug-treated means was assumed if P < 0.05. Analyses were performed using Statsdirect statistical software version 2.3. 1, 2003 (StatsDirect LTD, Cheshire, UK). The CAR of 3TC was unaffected by ddI, but TDF significantly (P < 0.05) reduced uptake ( Figure  1A) . Similarly, ABC significantly (P < 0.001) decreased the CAR of Figure 1D ).
Results and Discussion
Results
The average levels of P-gp, MRP1 and BCRP were 0.61 ± 0.23, 16.94 ± 5.03 and 0.55 ± 0.14, respectively, but there was no relationship between individual transporter expression for each PBMC sample and the CAR values for any drug.
Discussion
The rapidity (within 12 weeks of treatment start) with which treatment failure develops and the emergence of resistance mutations is surprising for the highly potent three drug combinations used in TDF-containing regimens. In order to find a mechanistic basis for this, we studied an important aspect of intracellular drug accumulation (i.e., lipophilicity), used primary human cells to investigate nucleoside/nucleotide interactions at the level of transport and also examined the effects of drug transporters on the accumulation of the compounds under investigation.
The octanol-saline partition coefficient determined for [ 14 C]-mannitol was similar to reported values [24] . We observed differential lipophilicity of the drugs with ABC being the most lipophilic and tenofovir the least ( Table 1) . The accumulation of all of the compounds was inhibited by incubation at 4 °C, but thie manipulation did not affect the accumulation of [ 3 H]-ABC ( Figure 1D ) due to its highly lipophilic nature. Interestingly, the rank order of accumulation of the drugs is identical to their lipophilicity. Although there is some evidence that some NRTIs/NtRTI are substrates of P-gp, BCRP and MRP [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , we observed that of the compounds tested, only [ 3 H]-ddI may be a P-gp substrate (data not shown). Our observation that [ 3 H]-3TC is not a P-gp substrate is in agreement with published literature [23] .
As evidence shows that some of the compounds under investigation are substrates of influx transporters such as hOATs and hOCTs [14, [24] [25] [26] , we postulate that they may compete for cellular entry which will consequently reduce the accumulation of the measured NRTI or NtRTI. Reciprocal to this, other studies have shown that ABC, 3TC and TDF inhibit the activities of P-gp and MRP [20] [21] [22] which would increase the accumulation of the labelled interacting drug. Here, we observed that the positive control inhibitors (dC and dipyridamole) significantly (P < 0. 37C °C) in the absence or presence of the drugs (at concentrations indicated) before the assays were terminated as described in the methods section. Each bar represents mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to control; n = 11. dC, deoxycytidine; dI, deoxyinosine; dG, deoxyguanosine. 
